ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News

It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and, on the same day, Aspire Bariatrics reached a key milestone with the PMA submission for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.

FDA OK'd its second obesity device this year on July 28, with the PMA approval for ReShape Medical Inc.'s ReShape weight-loss system. On the same day, Aspire Bariatrics Inc. announced a PMA submission for its AspireAssist aspiration therapy weight-loss device, reflecting the increasingly active field of prospective device competitors in the obesity space.

ReShape's integrated dual intragastric balloon system, which was previously CE marked, is designed to occupy space in the stomach to...

More from Archive

More from Medtech Insight